Clinical analysis of 27 patients with philadelphia positive acute lymphoblastic leukemia
10.3969/j.issn.1671-8348.2015.29.006
- VernacularTitle:27例成人Ph染色体阳性急性淋巴细胞白血病的临床分析
- Author:
Yuan YANG
;
Li WANG
- Publication Type:Journal Article
- Keywords:
philadelphia chromosome;
leukemia,lymphoid;
acute disease;
imatinib;
hematopoietic stem cell transplantation
- From:
Chongqing Medicine
2015;(29):4048-4050,4053
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical effects of imatinib and hematopoietic stem cell transplantation in Ph+acute lym‐phocytic leukemia(ALL) .Methods Collecting 27 new diagnosed patients with Ph+ ALL in which 19 were assigned to induction treatment with imatinib combined with chemotherapy(8 of IVD ,8 of VDLP and imatinib ,3 of VDP and imatinib) ,the other 8 cases were treated with conventional VDLP chemotherapy .22 patients after complete remission(CR) had maintenance therapy combined with imtinib ,3 patients had maintenance therapy without imtinib .Followed‐up the blood routine examination ,bone marrow aspira‐tion and ABL fusion gene ,6 patients had hematopoietic stem cell transplantation(one was auto‐HSCT ) .Results The CR rate of imatinib combined was higher than the patients without imatinib(89 .5% vs .50 .0% ,P<0 .05) ,the induction mortality rate was al‐so higher (0 vs .12 .5% ,P<0 .05) .The median remission duration of imatinib combined and without imatinib were (10 .0 ± 1 .4) months and 2 .0 months (P<0 .05) .The disease‐free survival(DFS) was significantly longer in patients received allo‐HSCT than in those received chemotherapy only (83 .3% vs .12 .6% ,P<0 .05) ,but the 2 year overall survival(OS) rate was not significantly dif‐ferent(75 .0% vs .14 .0% ,P>0 .05) .Conclusion Imatinib is effective for the induction therapy of Ph+ ALL .The remission dura‐tion of patients who received HSCT is obviously longer than those who received chemotherapy only .
